Products
Simoctocog alfa was approved in the EU in 2014 and in many countries in 2016 as a powder and solvent for the preparation of a [solution for injection>injections] (Nuwiq).
Structure and properties
Simoctocog alfa is a variant of blood clotting factor VIII lacking the B domain of the protein. The sequence is comparable to the 90- and 80-kDa forms of human factor VIII. Simoctocog alfa consists of 1440 amino acids and is produced by biotechnological methods. Because the glycoprotein is produced in a human cell line, it contains appropriate posttranslational modifications and is therefore less immunogenic.
Effects
Simoctocog alfa (ATC B02BD02) replaces factor VIII, which plays an important role in blood clotting, and reduces the risk of bleeding.
Indications
For prevention and treatment of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage
According to the SmPC. The drug is administered as intravenous.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
No information on drug-drug interactions is available.
Adverse effects
Possible adverse effects include paresthesias, headache, dizziness, dry mouth, back pain, injection site reactions, and rarely allergic reactions.